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Abstract
Systemic lupus erythematosus is a complement-mediated
autoimmune disease. While genetic deficiencies of classical
pathway components lead to an increased risk of developing
systemic lupus erythematosus, end organ damage is associated
with complement activation and immune complex deposition.
The role of classical pathway regulators in systemic lupus
erythematosus is unknown. C4 binding protein (C4bp) is a
major negative regulator of the classical pathway. In order to
study the role of C4bp deficiency in an established murine
model of lupus nephritis, mice with a targeted deletion in the
gene encoding C4bp were backcrossed into the MRL/lpr
genetic background. Compared with control MRL/lpr mice,
C4bp knockout MLR/lpr mice had similar mortality and similar
degrees of lymphoproliferation. There were no differences in the
extent of proteinuria or renal inflammation. Staining for
complement proteins and immunoglobulins in the kidneys of
diseased mice revealed no significant strain differences.
Moreover, there was no difference in autoantibody production or
in levels of circulating immune complexes. In comparison with
C57BL/6 mice, MRL/lpr mice had depressed C4 levels as early
as 3 weeks of age. The absence of C4bp did not impact serum
C4 levels or alter classical pathway hemolytic activity. Given that
immune complex renal injury in the MRL/lpr mouse is
independent of Fc receptors as well as the major negative
regulator of the classical pathway, new mechanisms for immune-
complex-mediated renal injury need to be considered.
Introduction
The complement system is an important mediator of tissue
injury in systemic lupus erythematosus (SLE) and other
immune complex diseases. SLE is characterized by systemic
complement activation, autoantibody production, the forma-
tion of circulating immune complexes, and the generation of
autoreactive lymphocytes associated with multisystem injury,
including nephritis, arthritis, serositis, dermatitis, and blood
dyscrasias. Lupus nephritis is mediated in part by local depo-
sition of circulating immune complexes and complement acti-
vation products. The relationship of complement to the
pathogenesis of SLE is a complex one. Genetic deficiencies in
the early components of the classical complement pathway
(C1 inhibitor, C1q/r/s, C2, or C4) are some of the strongest
risk factors for the development of SLE [1]. This is thought to
be due to the role of the early classical pathway of comple-
ment activation in the clearance of immune complexes and
apoptotic cells. Systemic complement activation, however,
marked by depression of serum C3 and C4 levels and periph-
eral deposition of these proteins, is associated with increased
disease activity [2,3].
The complement system can be activated by three pathways:
the classical pathway and the lectin pathway both require the
fourth component of complement (C4), while the alternative
pathway is independent of C4. All three pathways activate C3
by forming an enzyme, the C3 convertase, which cleaves C3
generating the C3a anaphylatoxin and the activation product
C3b. The product C3b mediates a number of cellular reac-
tions leading to proliferation and cell activation, release of
proinflamatory cytokines, increased vascular permeability, cell
recruitment, apoptosis, and, ultimately, parenchymal damage
[4].
C4 binding protein (C4bp) negatively regulates activation of
the classical pathway and the lectin pathway [5-7]. Function-
B6 = C57BL/6; BSA = bovine serum albumin; C4bp = C4 binding protein; CTRL = control; ELISA = enzyme-linked immunosorbent assay; Fc = 
crystallizable fragment; H & E = hematoxylin and eosin; HPLC = high-performance liquid chromatography; KO = knockout; MRL = MRL/MpJ-Tnfrsf6lpr; 
PBS = phosphate-buffered saline; SLE = systemic lupus erythematosus.Page 1 of 10
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tion of and promoting the decay of the classical pathway C3
convertase. It acts via three mechanisms: preventing the for-
mation of the C3 convertase by binding to C4b; accelerating
the natural decay of the classical pathway C3 convertase; and
as a cofactor for the serine proteinase factor I in the proteolytic
inactivation of C4b, which prevents the formation of the C3
convertase. Deficiency of C4bp would be expected to result in
increased cleavage of C3 and in increased complement activ-
ity in response to classical pathway or lectin pathway activa-
tion by immune complex formation, bacterial infections,
apoptosis, and other triggering mechanisms.
C4bp is present in human serum at concentrations of approx-
imately 200 mg/l [8]. Human C4bp is synthesized primarily in
the liver, and to a lesser degree by activated monocytes [9]. It
is an acute phase reactant [10,11], with expression upregu-
lated by proinflammatory cytokines [9,11]. In addition, C4bp
protein levels have been shown to be upregulated in SLE [10].
Only one patient with C4bp deficiency has been described
[12]. She had levels that were 15–29% of normal with
repeated testing by radioimmunodiffusion. The patient pre-
sented at age 33 years with recurrent oral and genital ulcers,
angioedema, malar rash, photosensitivity, dysuria, undetecta-
ble antinuclear antibodies, and normal C1 inhibitor levels.
Biopsy of her skin lesions revealed arteriolar vasculitis with
perivascular monocytic infiltrates, and increased C3 and IgM
staining. The patient was diagnosed with atypical Behcet's
disease and was treated with solumedrol and cyclophospha-
mide. Genotyping was not reported, but her father and her sis-
ter were reported to have similarly low serum C4bp levels [13].
There have been no reported cases of C4bp deficiency in
patients with SLE.
C4bp belongs to a gene family of structurally related proteins
designated the regulators of complement activation. There are
three isoforms of C4bp in humans [6]. The predominant form
is a 570 kDa glycoprotein composed of seven α chains cova-
lently bound to each other and to one β chain. Other isoforms
contain either seven α chains without a β chain or six α chains
with one β chain. The α chain is composed of eight comple-
ment control protein domains, and the N-terminal three com-
plement control proteins bind C4b [14]. The C-terminus
contains a separate domain critical for multimerization. The β
chain contains three complement control protein domains.
Human C4bp has been shown to bind other compounds
including protein S (β chain), C-reactive protein, serum amy-
loid protein, soluble CD40 ligand, CD40 (α chain), heparin (α
chain), low-density lipoprotein receptor protein (α chain), and
several bacterial peptides (α chain) [6,15-21]. Isoforms con-
taining the β chain can also bind to negatively charged phos-
pholipids on the surface of apoptotic cells in a protein-S-
dependent manner [22]. All isoforms regulate complement in
an equivalent manner, and no binding partner has been shown
to modulate C4bp complement regulatory activity.
The structure of murine C4bp differs from its human ortholog.
The mouse protein lacks the β chain [23] and the murine α
chain lacks two complement control protein domains and four
cysteines present in human C4bp[24]. C4bp protein circu-
lates in mouse serum as a multimer of noncovalently linked α
chains [25]. Protein levels are elevated in serum during the
acute phase response [26], and males have higher serum lev-
els than females (160 mg/l versus 60 mg/l) due to an effect of
testosterone [27,28]. Expression of the murine C4bp α-chain
mRNA has only been reported in the liver and in the epididymis
[24,29,30]. As shown with human C4bp the mouse C4bp
binds both mouse C4b in vivo and in vitro [25,27], and mouse
C4 is unable to form a functional C3 convertase when bound
to C4bp [27]. We recently reported the phenotype of the
C4bp knockout mouse [31]. Serum from the mice had
depressed C4 levels and increased hemolytic activity using
antibody-coated sheep erythrocytes.
There are several potential mechanisms by which C4bp defi-
ciency may modify disease progression in SLE. Reduced clas-
sical pathway regulation could enhance the ability to clear
apoptotic cells, thereby reducing the supply of autoantigens.
Similarly, an unregulated C3 convertase could generate more
C3 for opsonization and clearance of immune complexes, thus
limiting accumulation of these complexes in the kidney and
other organs. Alternatively, local classical pathway dysregula-
tion in the kidney could lead to increased inflammation and
exacerbation of tissue damage.
To study the role of C4bp in SLE, we used a C4bp knockout
mouse in an established experimental model. The MRL/lpr
mouse is a spontaneous disease model for complement-asso-
ciated inflammatory kidney disease, similar to lupus nephritis
[32]. The lpr mutation, a retroviral transposon insertion in the
FAS gene, results in loss of FAS function and thus a defect in
FAS-mediated apoptosis [33]. When present on the MRL
genetic background, the loss of FAS-mediated apoptosis
results in massive lymphoproliferation with expansion of the
B220+CD3+CD4-CD8- cell population and the generation of
autoreactive T cells [34]. The ensuing autoimmune disease is
characterized by lymphadenopathy, complement activation,
severe immune complex renal disease, and 50% lethality by
20–24 weeks of life [35]. We report here that C4bp defi-
ciency does not modify disease severity in MRL/lpr mice.
Materials and methods
Mice
MRL/MpJ-Tnfrsf6lpr (Jackson Laboratories, Bar Harbor, ME,
USA) and C4bp-/-C57BL/6 mice [31] were maintained in our
animal colony. Backcrossing was performed using a speed
congenics approach [36], and breeding of F3 mice was lim-
ited to those with >70% of screened loci encoding MRL alle-Page 2 of 10
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chromosome 1 (D1Mit380 and D1Mit111) was performed to
minimize the interval of 129 sequence surrounding the C4bp
gene (67.6 cM on chromosome 1), as 129 alleles at multiple
loci on this chromosome have been linked to enhanced
autoantibody production [37]. After the third and sixth back-
cross, mice were bred to generate Faslpr/lprC4bp-/- (KO MRL)
mice, Faslpr/lprC4bp+/- mice, and Faslpr/lprC4bp+/+ (CTRL MRL)
mice. Additional genotyping was not performed on the F6
mice but they were assumed >95% MRL genotype. These
studies were reviewed and approved by the UTHSC-H Animal
Welfare Committee.
Immunophenotyping
Leukocytes were obtained from the spleens and axillary lymph
nodes at 20 weeks of age. Cell populations were character-
ized with the following markers: CD3 (clone 145-2C11), CD4
(GK1.5), CD8 (53-6.7), CD25 (PC61.5), CD38 (90), CD19
(MB19-1), CD27 (LG.7F9), IgD (11–26c), CD11b (M1/70),
and GR-1(Ly-6G) from eBiosciences (San Diego, CA, USA)
and CD45R/B220 (RA3-6B2) and CD138 (281-2) from BD
Pharmingen ( San Diego, CA, USA). A minimum of 10,000
events were collected and analyzed on a FACSCaliber using
CellQuest software (BD Biosciences San Jose, CA, USA).
Samples were obtained from five or six mice per group.
Renal function
Timed urine collections were obtained from mice at 8, 12, 16,
and 20 weeks of age. Urinary protein concentration was deter-
mined by BCA assay (Pierce, Rockford, IL, USA) and 24-hour
excretion was normalized for body weight. Samples were
measured in duplicate with 7–10 animals per group. Serum
creatinine was measured by HPLC as previously described
[38].
Histologic analysis
Renal tissue was fixed in PBS-buffered 4% formalin, dehy-
drated and embedded in paraffin. Four-micron sections were
stained with H & E or with periodic acid Schiff. Glomerular
injury was graded in a blinded manner, with a minimum of 20
glomeruli scored per animal per group, as follows: the percent-
age of glomeruli containing cellular crescents, the percentage
of glomeruli with sclerosis involving >25% of the glomerular
tuft, and the degree of hypercellularity (0–3 scale).
Tubulointerstitial disease was graded on a 0–4 scale as fol-
lows: 0, no cellular infiltrates with back-to-back tubules, no evi-
dence of fibrosis; 1, 0–5 cells per high-power field with
minimal fibrosis; 2, 5–10 cells/high-power field with moderate
fibrosis; and 3, >10 cells/high-power field with marked
fibrosis.
Perivascular inflammation was graded on a 0–3 scale: 0, no
cellular infiltrates surrounding branching arterioles or branch-
ing veins; 1, <10 cells; 2, <10 layers of cells; 3, >10 layers of
cells.
Immunostaining
OCT-embedded (optimal cutting temperature compound)
snap-frozen 4 μm sections were stained with the following
antibodies: FITC-conjugated goat anti-murine C3 (Cappel,
Solon, OH, USA), FITC-conjugated goat anti-mouse IgG
(Zymed/Invitrogen, Carlsbad, CA, USA), FITC-conjugated
anti-mouse C1q (Cedarlane, Burlington, NC, USA), and rat
anti-mouse C4 (Accurate, Westbury, NY, USA). For C4 stain-
ing, FITC-conjugated donkey anti-rat IgG was used for detec-
tion of primary antibody after absorbing for 15 min with normal
mouse serum (Jackson ImmunoResearch, West Grove, PA,
USA). Control staining was also performed using matched iso-
types or IgG (data not shown).
Staining was quantified by incubation of sections with serial
dilutions of antibody; endpoint titers were similar for all four
antibodies between KO MRL mice and CTRL MRL mice.
Staining was scored in a blinded manner on a relative scale of
0–3 using dilutions for each antibody on the linear portion of
the titration curve.
Autoantibody titers
Serum levels of antidouble-stranded DNA antibodies were
measured by ELISA. Double-stranded DNA was derived by S1
nuclease (Boehringer/Roche, Indianapolis, IN, USA) treatment
of calf thymus DNA (Rockland Gilbertsville, PA, USA). Wells
were coated with 50 μg/ml poly-L-lysine overnight at 4°C, and
then with 10 mg/ml double-stranded DNA at 37°C for 2 hours.
After washing with PBS, sera were added in serial dilutions
starting at 1/100 and incubated for 60 minutes at room tem-
perature. After washing, horseradish peroxidase-conjugated
goat anti-mouse IgG antibody or isotype-specific antibody
(Jackson Immunoresearch) was added, followed by TMB
(Pierce) for color development.
Circulating immune complexes and serum complement 
assays
Blood was collected from the mice at the time of sacrifice and
serum was prepared by clotting for 2 hours at 37°C followed
by centrifugation. Circulating immune complex levels were
determined by the C1q ELISA method previously described
[39], with the following modifications. High protein binding
plates (NUNC Maxisorp, Thermo Fisher Scientific) were
coated with 1 μg/ml human C1q (AbD Serotec, Raleigh, NC,
USA) in 0.1 M carbonate buffer (pH 9.6) for 48 hours at 4°C,
and were then blocked for 2 hours at room temperature with
1% BSA in PBS. Serum samples were added in serial dilu-
tions starting at a 1/50 dilution and plates were incubated for
2 hours. After washing with PBS 0.05% Tween-20, bound
complexes were detected with horseradish peroxidase-conju-
gated goat anti-mouse IgG (BioRAD, Hercules, CA, USA).
Color development was measured at 450 nm after incubationPage 3 of 10
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Mouse IgG was heat aggregated for 30 minutes at 37°C and
was used as a positive control. Binding was measured in
arbitrary units and normalized to binding of pooled normal
mouse serum, used as a negative control (Jackson
Immunoresearch).
The C3 and C4 levels in serum were measured by semiquan-
titative ELISA. Plates were coated with either goat anti-mouse
C3 (Cappel) or rat anti-mouse C4 (Accurate) in carbonate
buffer (pH 9.6) and were incubated overnight at 4°C. After
washing and blocking with 5% BSA in PBS for 2 hours, sera
were added in serial dilutions, starting at 1/100 and 1/10,
respectively, and were incubated for 1 hour at room tempera-
ture. Bound protein was detected using horseradish peroxi-
dase-conjugated goat anti-mouse C3 (Cappel) or rabbit anti-
human C4c (Dako, Glostrup, Denmark) with horseradish per-
oxidase-conjugated donkey anti-rabbit IgG (Jackson Immu-
noresearch). Color development was measured at 450 nm
after incubation with TMB substrate (Pierce) and quenching
with sulfuric acid. Pooled normal mouse sera (Jackson Immu-
noresearch) was used as a positive control.
Classical pathway complement activity was measured by
hemolytic assay. Sera were diluted in gelatin veronal buffer
containing calcium and magnesium and were then added to
IgM-sensitized sheep erythrocytes in 13 × 100 mm2 glass test
tubes (Complement Tech, Tyler, TX, USA). The percentage
lysis at 37°C was determined after 1 hour. Reactions were
stopped by adding ice-cold buffer and then removing cells by
centrifugation at 3,000 rpm for 10 minutes at 4°C. Absorb-
ance was read at 412 nm. Each serum sample was tested
alone as a negative control, and incubation of sheep erythro-
cytes without serum was used to determine spontaneous lysis.
One hundred percent lysis was defined as absorbance after
incubation in hypo-osmolar buffer. The percentage lysis was
calculated as follows:
C57BL/6 serum was used as a positive control.
Statistics
The figures show the means, with error bars reflecting the
standard error of the mean. A two-tailed unpaired Student's t
test was used to test for significant differences between
groups. The Mann–Whitney test was used to determine the
significance of changes in histologic score and immunofluo-
rescence data. Comparisons of serum C4 levels were ana-
lyzed by analysis of variance with a Bonferonni P value
correction. Kaplan–Meier analysis was performed on survival




C4bp-/-C57BL/6 (KO B6) mice were back-crossed six gener-
ations onto the MRL genetic background. C4bp+/- MRL mice
were then intercrossed to obtain homozygous KO MRL mice
and CTRL MRL control mice. These intercrosses resulted in
the expected Mendelian ratios of homozygote and heterozy-
gote progeny. MRL mice exhibit 50% mortality at 20 weeks of
age [40]. Compared with CTRL MRL mice, the KO MRL mice
had equivalent survival up to 34 weeks (Figure 1, 50% mortal-
ity 22 weeks). By 20 weeks, there was a significant reduction
in body mass in KO MRL mice (39 ± 0.9 g) compared with
CTRL MRL mice (43.3 ± 0.9 g, P < 0.005). Mice were sacri-
ficed at this age for all further studies. Similar studies in F3
mice yielded an overlapping survival curve.
MRL mice develop massive lymphoproliferation with a prepon-
derance of T cells in the lymph nodes and surrounding large
vessels. There was a modest increase in the weight of axillary
lymph nodes in KO MRL mice (798 ± 163 g) compared with
CTRL MRL mice (502 ± 61 g, P < 0.05); however, there was
no difference in splenomegaly (KO MRL mice, 702 ± 107 g;
CTRL MRL mice, 791 ± 275 g; P > 0.05) or in the weight of
the renal draining lymph nodes (KO MRL mice, 459 ± 113 g;
CTRL MRL mice, 459 ± 118 g; P > 0.05). The KO MRL mice
and CTRL MRL mice both developed large perivascular infil-
trates in multiple organs including the lungs, the liver, the prox-
imal small bowel, and the colon.
Detailed phenotypic analysis of lymphoid populations was per-
formed. As expected, all MRL mice had expanded lymphocyte
populations, primarily in CD4-CD8- double-negative T cells. By
flow cytometry, the absolute numbers of CD4+ T cells, CD8+
T cells, and CD4-CD8- double-negative T cells in both the
Percentage lysis
OD  hemolytic test OD  negative co= −412 412( ) ( ntrol
OD   lysis OD  spontaneous lysis
)





No difference in survival between knockout MRL mice and control MRL mice
mice. C4bp-/-MRL/lpr (KO MRL) mice (solid line, n = 38) and littermate 
control (CTRL MRL) mice (dashed line, n = 34) from the F6 backcross 
were followed for up to 34 weeks. Mortality was quantified using Kap-
lan–Meier analysis. P = 0.15, KO MRL mice versus CTRL MRL mice 
(log-rank).Page 4 of 10
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ble with those in CTRL MRL mice (Table 1). To determine
whether C4bp was important in B-cell responses in germinal
centers, the proportions of IgD+CD27- naïve B cells,
CD27+CD38+ centroblasts, CD27+CD38- memory B cells,
and IgD-CD138+ plasma B cells were measured. There were
no differences in these B-cell subsets between KO MRL mice
and CTRL MRL mice.
Renal injury
MRL mice typically have chronic kidney disease characterized
by proteinuria and renal insufficiency. Timed urine collections
were performed in KO MRL mice and CTRL MRL mice at 8,
12, 16, and 20 weeks of age. Consistent with the model, there
were age-dependent increases in protein excretion in both
sets of mice; however, the degree of proteinuria was equiva-
lent at all time points. At 20 weeks, KO MRL mice had a mean
protein excretion of 0.53 ± 0.08 mg/g/day compared with
0.48 ± 0.05 mg/g/day in CTRL MRL mice (Table 2, P = 0.53).
Moreover, KO MRL mice and CTRL MRL mice had abnormal
elevations in serum creatinine, but the degree of elevation was
only modestly lower in KO MRL mice (0.16 ± 0.03 mg/dl;
CTRL MRL mice, 0.20 ± 0.04 mg/d; P = 0.39).
Histologically, KO MRL mice and CTRL MRL mice had prolif-
erative glomerulonephritis, tubulointerstitial inflammation with
fibrosis, and large perivascular infiltrates (Figure 2). There
were equivalent degrees of glomerular hypercellularity and
similar proportions of glomerular crescents. Scoring revealed
a modest decrease in glomerulosclerosis in KO MRL mice
(Table 2) but there was large variability between mice, which
impacted the statistical significance (P = 0.09). Histologic
scores for tubulointerstitial disease and periglomerular leuko-
cyte accumulation (P = 0.87 and P = 0.78, respectively) were
identical in KO MRL mice and CTRL MRL mice (Table 2).
There was a two-fold decrease in the perivascular leukocyte
number in KO MRL mice kidneys (P < 0.0001; Figure 2). Scor-
ing of kidney pathology was performed at 20 weeks on all
Table 1
Splenic and lymph node T-cell and B-cell subsets
C4bp knockout MRL mice (n = 5) Littermate control MRL mice (n = 3)
CD4/CD8 ratio 0.42 ± 0.14 0.60 ± 0.34
Double-negative T-cell (%) 54 ± 4 49 ± 10
Naïve B cells (%) 49 ± 10 43 ± 10
Lymph node centroblasts (%) 29 ± 3 32 ± 4
Memory B cells (%) 6 ± 2 5 ± 0.01
Plasma B cells (%) 0.4 ± 0.2 0.3 ± 0.2
Table 2
Renal disease in C4bp knockout MRL mice compared with littermate control MRL mice
C4bp knockout MRL mice (n = 16) Littermate control MRL mice (n = 13)
Proteinuria (mg/g/day) 0.53 ± 0.08 0.48 ± 0.05
Serum creatinine (mg/dl) 0.16 ± 0.03 0.20 ± 0.04
Hypercellularity 1.9 ± 0.2 2.0 ± 0.3
Crescents (%) 9 ± 4 11 ± 6
Sclerosis (%) 17 ± 7 38 ± 9
Periglomerular leukocytes 14 ± 3 15 ± 2
Tubulointerstitial disease 1.4 ± 0.3 1.3 ± 0.3
Vasculitis 1.3 ± 0.1* 2.4 ± 0.2
IgG staining 2.0 ± 0.2 2.0 ± 0.2
C3 staining 1.5 ± 0.2 1.6 ± 0.3
C4 staining 1.3 ± 0.2 1.3 ± 0.1
C1q staining 0.6 ± 0.1 0.8 ± 0.1
*P < 0.0001.Page 5 of 10
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that the progression of disease in both genders was equiva-
lent between strains.
The pathogenesis of glomerular disease in the MRL mouse
involves immune complex accumulation with deposition of cir-
culating complement proteins as well as increased localized
complement production. Immunofluorescent antibody staining
showed large amounts of both complement protein C3 and
IgG in the glomerular mesangium and in the capillary loops
(data not shown). There were no differences in the degree of
staining in KO MRL mice and CTRL MRL mice as measured
by serial dilution of antibody or by scoring of representative
glomeruli by blinded observers (P = 0.55 and P = 1.0, respec-
tively; Table 2). The degree of local complement activation via
the classical pathway was also assessed in the kidney by
immunostaining. The KO MRL mice kidneys and the CTRL
MRL mice kidneys had similar degrees of C1q and C4 (P =
0.55 and P = 1.0, respectively; Table 2). There were also no
differences in complement and IgG staining at earlier time
points. Therefore, there appeared to be no differences in renal
handling of immune complexes by KO MRL or CTRL MRL
mice.
Systemic immune responses
MRL mice have lymphoproliferation and autoantibody produc-
tion due to loss of tolerance. KO MRL mice and CTRL MRL
mice both had elevated antidouble-stranded DNA antibody tit-
ers by 20 weeks of age compared with pooled serum from
nonautoimmune mice (Figure 3, endpoint titer 1:204,800 in
both KO MRL and CTRL MRL mice sera). Moreover, there
were no differences in titers of the IgG1 (Th2-predominant) or
IgG2a (Th1-predominant) autoantibody subsets (endpoint tit-
ers 1:51,200 and 1:204,800, respectively).
As a consequence of high titers of autoantibodies, MRL mice
have increased production of antibody–antigen immune com-
plex in the circulation. These immune complexes are cleared
by the reticuloendothelial system, in part due to opsonization
and solubilization by complement proteins. To determine
whether C4bp knockout mice had an altered ability to clear
immune complex due to impaired classical pathway comple-
ment regulation, we measured immune complex levels in the
serum of 20-week-old mice. KO MRL mice serum and CTRL
MRL mice serum had significantly more immune complex than
normal mouse sera. There was no difference in immune com-
plex levels in KO MRL mice compared with CTRL MRL mice
Figure 2
Renal histopathology in knockout MRL mice and control MRL mice. Sections showing the renal histopathology of C4bp-/-MRL/lpr(KO MRL) mice 
and littermate control (CTRL MRL) mice. (a) Representative formalin-fixed sections from the kidney stained with periodic acid Schiff (0.75NA, 400× 
magnification). Glomeruli with crescentic changes are shown. (b) Sections stained with periodic acid Schiff showing perivascular inflammation 
around branching arteries (white arrows) (0.15NA, 50× magnification).Page 6 of 10
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burdens of circulating immune complexes were KO MRL mice.
To determine whether modest increases in circulating immune
complex levels could be explained by relative decreases of
classical pathway complement proteins in the circulation of
C4bp knockout mice, C3 and C4 levels were measured by
semiquantitative ELISA. At 20 weeks of age, both C3 and C4
levels in KO MRL mice were equivalent to levels in CTRL MRL
serum (Figure 4). C4 levels were also equivalent at 8 weeks of
age. Of note, the levels of C4 in CTRL MRL mouse serum
were 16-fold lower than those measured in wildtype CTRL B6
mice or in KO B6 mice (P < 0.001). In CTRL MRL mice, the
serum C4 levels rise four-fold from 3 weeks of age to 8 weeks
of age and then remain unchanged until at least 20 weeks of
age. To confirm that there was no difference in basal classical
pathway activity in serum from the KO MRL mice compared
with that of CTRL MRL mice, complement hemolytic assays
were performed. There was no measurable difference
between KO MRL mice and CTRL MRL mice (P = 0.11), but
the activity of KO MRL and CTRL MRL sera was significantly
less than that of KO B6 serum or CTRL B6 serum (P < 0.001;
data not shown).
Discussion
We report the phenotype of C4bp-deficient MRL mice. Given
that the MRL mouse has long been held as a murine model of
the immune complex renal injury seen in patients with lupus
nephritis, it was surprising that mice lacking the critical regula-
tor of the classical pathway of complement activation had no
differences in mortality or morbidity compared with C4bp-suf-
ficient littermate control mice. There were no significant differ-
ences in the severity of renal injury between strains with
respect to the glomerular deposition of complement proteins
or immunoglobulins. Similarly there were no differences in
either the degree of glomerular proliferation, of periglomerular
inflammation, or of tubulointerstitial disease. In addition there
was no evidence of increased complement activation either
locally within the kidney or systemically in KO MRL mice at any
Figure 3
Similar serum autoantibody titers and circulating immune complexes in knockout MRL and control MRL mice
knockout MRL and control MRL mice. (a) Sera from C4bp-/-MRL/lpr 
(KO MRL) mice (▲, solid line, n = 15) and littermate control (CTRL 
MRL) mice (, dashed line, n = 8) were tested for binding to double-
stranded DNA by ELISA using serial serum dilution (x axis). Pooled nor-
mal mouse serum from nonautoimmune mice (■, NMS) was used as a 
negative control. P > 0.05, KO MRL mice versus CTRL MRL mice. 
OD450, optical density at 450 nm. (b) Sera from 20-week-old KO MRL 
mice (▲, n = 15) and littermate control mice (, CTRL MRL, n = 8) 
were tested for binding to human C1q by ELISA. Data for each individ-
ual mouse are shown and mean increases in immune complex levels 
are displayed as solid lines. P > 0.05, KO MRL mice versus CTRL MRL 
mice. AU, arbitrary units.
Figure 4
Serum C3 and C4 levels in knockout MRL mice, control MRL mice, and nonautoimmune mice
nonautoimmune mice. (a) Serum C3 levels from 20-week-old C4bp-/-
MRL/lpr (KO MRL) mice (n = 6) and littermate control (CTRL MRL) 
mice (n = 5) were measured by ELISA, and means values for 1:4,000 
dilution are shown. P > 0.05 at all dilutions tested. OD450, optical den-
sity at 450 nm. (b) Serum C4 levels from 20-week-old KO MRL mice (n 
= 13) and CTRL MRL mice (n = 9) were compared with levels from 
mice at different ages as well as 20-week-old KO C57BL/6 (B6) mice, 
CTRL B6 mice, and C4-deficient B6 mice (n = 3 for each). Serum lev-
els were measured by serial dilutions using sandwich ELISA, and mean 
values for 1:200 dilution are shown. *P < 0.001.Page 7 of 10
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way of complement activation, therefore appears to play a min-
imal role in modulating disease severity in the MRL mouse.
There are several possible explanations for the lack of pheno-
typic differences between the C4bp-deficient mice and the
control mice. First, it is possible that the classical pathway is
maximally activated in the setting of autoimmunity in the MRL
mouse, and that genetic targeting of C4bp does not increase
the classical pathway hemolytic activity as it does in nonau-
toimmune mice (Soimo and Wetsel, manuscript in
preparation). To investigate this possibility, serum C4 levels
were measured by ELISA at various ages. The data indicate
that, similar to humans, serum C4 levels rise early in life from 3
weeks to 8 weeks of age. After 8 weeks, the levels remain con-
stant until at least 20 weeks, when kidney disease becomes
evident. Interestingly, in comparison with CTRL MRL mice,
CTRL B6 mice had significantly higher hemolytic activity and
serum C4 levels. It is unlikely that these findings are due to
complement consumption mediated by either tissue deposi-
tion or circulating immune complexes in the MRL mouse, as at
8 weeks of age, prior to the onset of overt injury, serum C3 lev-
els were similar between the two strains (data not shown). It
would therefore appear that, with respect to CTRL B6 mice,
CTRL MRL mice have C4 deficiency marked by functional
reductions in classical pathway hemolytic activity.
Two C4 genes map to the H-2 region of mouse chromosome
17. The MRL strain is H-2k and encodes only one C4k allele,
which is aberrantly spliced in hepatocytes [41]. An intronic
insertion encodes an alternative 5' splice site, resulting in an
inframe stop codon in the mRNA and a truncated C4 protein
that is not secreted [42]. Nonhepatic tissues do not utilize this
splice site, and they express a full-length mRNA and a wildtype
protein [43,44]. As the majority of C4 in the serum is derived
from the liver, mice with the H-2k haplotype express 10-fold to
20-fold lower amounts of C4. C57BL/6 mice are H-2b and
encode C4 and a related protein Slp (sex-limited protein). The
C4b allele lacks the intronic insertion in C4k and is expressed
at higher levels, as we have confirmed. In addition, Slp is
expressed in high levels in male mice. These differences are
likely to explain the decreased hemolytic activity in MRL serum
compared with C57BL/6 serum. MRL mice and BXSB mice,
both mouse models for lupus-like disease, have previously
been described to have lower C4 levels than B6 mice [45].
The H-2 region maps to qualitative trait loci Sle4 and Lbw1,
both identified by genetic mapping in mouse models of SLE
[46,47]. It therefore seems more probable that the develop-
ment of autoimmunity in MRL mice is in part related to a func-
tional deficiency in C4, similar to that seen in humans with
deficiencies in early classical pathway components such as
C1q, C2, and C4.
As the local, nonhepatic, synthesis of C4 is normal in mice with
the H-2k allele, a second explanation for the lack of phenotype
in C4bp KO MRL mice is that the classical pathway plays only
a minor role in local complement-dependent injury in the MRL
mouse. C3 deposition in the kidney was much more intense
than C4 and C1q deposition, and this may be reflective of a
larger role for the alternative pathway in cleavage and deposi-
tion of C3. The alternative pathway requires factor B to form
the C3 convertase, and in the MRL background factor B
knockout mice have less proteinuria, decreased renal pathol-
ogy scores, less glomerular IgG staining, and less renal vascu-
litis [48]. Recent studies in a pure immune complex model of
renal injury additionally conclusively demonstrated that the
renal injury seen in this model was alternative pathway
dependent [49]. Alternatively, it is possible that the lack of dif-
ferences in local complement deposition and subsequent
renal injury may also be reflective of the relative contribution of
fluid phase regulatory proteins, such as C4bp, versus regula-
tory proteins expressed on the cell surface, such as MCP and
DAF. Our data combined with those reported in the factor-B-
deficient MRL mouse, however, strongly support the hypo-
thesis that the principal pathway that drives complement-
dependent renal injury in the MRL mouse is the alternative
pathway.
In addition to the primary role of C4BP in negatively regulating
classical pathway activation, C4bp has been proposed, either
directly or indirectly, to modulate a variety of biologic proc-
esses including hemostasis, B-cell activation, and immune
complex clearance. With respect to hemostasis, murine C4bp
lacks the β chain present in human C4bp, and thus is unable
to bind protein S. C4bp therefore plays no role in the mouse
system in regulating the coagulation cascade. It has recently
been reported that the α chain of C4bp has a functional role
in mediating B-cell proliferation and class switching via its
interactions with the CD40-CD40 ligand system. While this
interaction was not directly examined in the current report,
there were no differences in either absolute B-cell number,
serum levels of autoantibodies, or subclasses of antidouble-
stranded DNA antibodies between C4bp-sufficient mice or
C4bp-deficient mice. In the context of the MRL mouse, there-
fore, it appears that C4BP plays no role in the regulation of B-
cell responses. As an intact classical pathway is required for
proper clearance of immune complexes and apoptotic bodies,
C4bp as a negative regulator of the classical pathway should
impact clearance of immune complex by limiting the activity of
the classical pathway C3 convertase, and subsequent gener-
ation of C3b needed for solubilization of immune complexes.
We were unable, however, to demonstrate any difference in
circulating immune complex between the C4bp-sufficient
mice and C4bp-deficient mice. Although it is possible that the
reduced levels of C4 in the MRL strain limit the intrinsic capac-
ity of the classical pathway to generate C3b, there are data to
suggest that amplification of C3b generation via the alternative
pathway is required for immune complex clearance [50]. This
is believed to be due to the inefficiency of C3b binding to the
immune complex: only 10% of generated C3b binds to thePage 8 of 10
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therefore appears to have minimal impact on immune complex
processing when the Alternative Pathway is intact. Further
study of immune complex and apoptotic cell clearance in
C4BP and factor B knockout mice in a C4-sufficient genetic
background could confirm the relative importance of these two
pathways in immune complex clearance.
One notable finding in C4bp knockout mice kidneys was their
small perivascular infiltrates compared with very large infil-
trates seen in control mice. This finding was tissue specific, as
there were no differences in perivascular infiltrates in other tis-
sues. The biology of C4 and its cleavage products in the
mouse is unclear due to a paucity of reagents available for this
animal. It is possible that local production of C4 in the kidney
is more responsible for leukocyte accumulation in this than in
other organs. C4bp may be required for optimal cell recruit-
ment, perhaps due to binding of a chemotactic product of C4b
cleavage. Alternatively, C4bp may modulate kidney endothelial
cell function in a complement-independent manner. Nonethe-
less, differences in perivascular leukocyte accumulation in
renal vessels did not correlate with other histologic parame-
ters, with kidney function, or with survival.
Conclusion
In summary, the current studies in C4bp-deficient mice fail to
demonstrate any significant impact on survival or disease
severity in the MRL mouse model of lupus nephritis. Further-
more, this lack of impact on disease phenotype appears to be
due to a relative deficiency of C4 in the MRL mouse strain that
results in a functional reduction in the classical pathway hemo-
lytic activity. Given previous data showing that renal injury in
the MRL mouse is independent of Fc receptors [51], our stud-
ies showing the functional deficiency of C4 in these mice, and
that the loss of the major negative regulator of the classical
complement pathway fails to impact disease severity, the use
of the MRL mouse as a prototypical model of immune complex
renal injury may need to be reconsidered. Alternatively, new
mechanisms for immune-complex-mediated renal injury need
to be considered.
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